Teva loses bid to cancel Corcept drug patent at Federal Circuit – Reuters
Teva loses bid to cancel Corcept drug patent at Federal Circuit Reuters
In: PATENT NEWS
Teva loses bid to cancel Corcept drug patent at Federal Circuit Reuters
In: PATENT NEWS
The 1952 Patent Act separated novelty in Section 102 from patent eligibility in Section 101, and per Judge Michel and attorney John Battaglia, …
In: PATENT NEWS
Revitalization Partners Sues Google and YouTube for Patent Infringement Business Wire
In: PATENT NEWS
Teva Pharmaceuticals suffered a fresh legal setback on Tuesday in its effort to market a generic version of the synthetic steroid Korlym to treat …
In: PATENT NEWS
Teva Pharmaceutical (TEVA) has lost its attempt to invalidate a patent for Cushing’s syndrome drug Korlym, marketed by Corcept Therapeutics (CORT) …
In: PATENT NEWS
Company gets US patent for a way to secure DNS with blockchain … and they act as a single point of failure in the trust chain of the web.
In: PATENT NEWS
In 2021, we saw the first global court decisions to grapple with whether a non-human can be an inventor for the purposes of patent law.
In: PATENT NEWS
Patent box: Wait continues but govt commits to 2022 launch https://www.innovationaus.com/
In: COPYRIGHT NEWS
Venture Capital-Backed Matidor and Vincent Lam Found Liable for Intellectual Property Infringement by Federal Court Financial Post
In: PATENT NEWS
… in which approved the amended Patent Law (Regulation) for the Gulf Cooperation states, the Cooperative Commercial Committee of the GCC Council …
Designed by Industrial Action
Copyright © 2025 OPUS IP Limited. All Rights Reserved
OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION